Tideglusib, a selective non-ATP-competitive GSK-3β inhibitor [72], has been applied in clinical trials for several neurological diseases, including AD [73], myotonic dystrophy type 1 [74], progressive supranuclear palsy [75], and amyotrophic lateral sclerosis [76]. Here, GSK3B is linked to amyotrophic lateral sclerosis.